COSMOS Pharmaceutical Future Growth

How is COSMOS Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

7.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

TSE:3349 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
5/31/2025	959,664	27,398	8,754	51,275	10
5/31/2024	893,234	25,246	5,667	48,118	11
5/31/2023	825,196	23,691	1,534	45,710	11
11/30/2022	788,292	23,209	-3,655	41,973	N/A
8/31/2022	772,127	23,393	N/A	N/A	N/A
5/31/2022	755,414	23,155	-11,303	32,194	N/A
2/28/2022	743,612	22,030	N/A	N/A	N/A
11/30/2021	733,387	25,329	-5	35,596	N/A
8/31/2021	726,672	25,909	N/A	N/A	N/A
5/31/2021	726,424	27,156	1,811	27,875	N/A
2/28/2021	733,223	28,777	N/A	N/A	N/A
11/30/2020	723,309	25,736	28,882	50,935	N/A
8/31/2020	709,064	23,876	N/A	N/A	N/A
5/31/2020	684,403	21,435	39,513	65,461	N/A
2/29/2020	653,527	20,217	N/A	N/A	N/A
11/30/2019	638,034	18,951	10,653	38,209	N/A
8/31/2019	622,103	19,349	N/A	N/A	N/A
5/31/2019	611,137	19,185	5,339	34,379	N/A
2/28/2019	597,715	18,966	N/A	N/A	N/A
11/30/2018	585,536	18,857	1,302	30,947	N/A
8/31/2018	572,807	17,880	N/A	N/A	N/A
5/31/2018	557,999	17,633	3,135	32,586	N/A
2/28/2018	542,936	17,510	N/A	N/A	N/A
11/30/2017	526,523	17,313	6,814	35,488	N/A
8/31/2017	514,880	18,239	N/A	N/A	N/A
5/31/2017	502,732	18,215	8,271	36,938	N/A
2/28/2017	490,037	15,812	N/A	N/A	N/A
11/30/2016	477,739	14,981	5,955	34,300	N/A
8/31/2016	463,517	13,679	N/A	N/A	N/A
5/31/2016	447,273	12,435	N/A	30,986	N/A
2/29/2016	433,328	12,738	N/A	N/A	N/A

Earnings vs Savings Rate: 3349's forecast earnings growth (7.2% per year) is above the savings rate (0.04%).

Earnings vs Market: 3349's earnings (7.2% per year) are forecast to grow slower than the JP market (8.3% per year).

High Growth Earnings: 3349's earnings are forecast to grow, but not significantly.

Revenue vs Market: 3349's revenue (7.5% per year) is forecast to grow faster than the JP market (4.1% per year).

High Growth Revenue: 3349's revenue (7.5% per year) is forecast to grow slower than 20% per year.

Future ROE: 3349's Return on Equity is forecast to be low in 3 years time (11.3%).